TSE:4507Pharmaceuticals
Shionogi’s Olorofim Phase 3 Success And XOCOVA Expansion Might Change The Case For Investing In Shionogi (TSE:4507)
Shionogi & Co., Ltd. recently reported positive global Phase 3 results for its novel antifungal olorofim and secured supplemental approval in Japan for expanded pediatric use and a new 25 mg tablet formulation of its COVID-19 drug XOCOVA.
Together, these advances highlight Shionogi’s strengthening role in infectious disease treatments, spanning both life-threatening invasive fungal infections and broader, age-inclusive COVID-19 care.
We’ll now examine how olorofim’s successful Phase 3...